ALGORAE PHARMACEUTICALS LIMITED - Announcements

0.00%

0.6¢

Market Cap $10.96M

Healthcare Biotechnology

Algorae Pharmaceuticals Limited is an Australia-based artificial-intelligence (AI)... Algorae Pharmaceuticals Limited is an Australia-based artificial-intelligence (AI) enabled drug discovery and development company. The Company is actively engaged in expanding its therapeutic pipeline using a proprietary artificial intelligence (AI) drug discovery and development platform, known as Algorae Operating System (AlgoraeOS). The AI platform leverages extensive medical and scientific databases from various disciplines within an advanced system at the intersection of AI and pharmaceutical research. By employing machine learning, deep learning, and neural networks, the AlgoraeOS is focused on uncovering synergistic fixed dose drug combinations that lead to the development of effective treatments for any medical condition. It is also focused on advancing its drug candidates, which include AI-116 for the treatment of neurodegenerative disorders and/or dementia, and AI-168 for cardiovascular disease and NTCELL for Parkinson’s disease.More

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

1AI	Quarterly Activities Report /Appendix 4C Cash Flow Statement	PRICE SENSITIVE	29/07/25	1.01MB	Share
1AI	Algorae Receives A$318,771 R&D Cash Rebate from ATO	PRICE SENSITIVE	06/06/25	186.28KB	Share
1AI	Peter Mac Partners with Algorae on AI Drug Targets	PRICE SENSITIVE	08/05/25	256.29KB	Share
1AI	Quarterly Activities Report /Appendix 4C Cash Flow Statement	PRICE SENSITIVE	29/04/25	977.98KB	Share
1AI	Algorae Receives A$451,359 R&D Cash Rebate from ATO	PRICE SENSITIVE	31/03/25	186.37KB	Share
1AI	Half Yearly Report Announcement and Appendix 4D	PRICE SENSITIVE	26/02/25	1.16MB	Share
1AI	Quarterly Activities Report /Appendix 4C Cash Flow Statement	PRICE SENSITIVE	29/01/25	1.08MB	Share
1AI	Significant Cardioprotection Qualities in AI-168 Studies	PRICE SENSITIVE	29/11/24	344.06KB	Share
1AI	24 New AI-Generated Drug Targets	PRICE SENSITIVE	21/11/24	261.28KB	Share
1AI	Quarterly Activities Report /Appendix 4C Cash Flow Statement	PRICE SENSITIVE	23/10/24	527.26KB	Share
1AI	AlgoraeOS Artificial Intelligence Platform Launched	PRICE SENSITIVE	24/09/24	17.67MB	Share
1AI	Annual Report and Appendix 4E	PRICE SENSITIVE	30/08/24	1.2MB	Share
1AI	Positive results from AI-116 in vitro studies	PRICE SENSITIVE	31/07/24	336.91KB	Share
1AI	Quarterly Activities Report /Appendix 4C Cash Flow Statement	PRICE SENSITIVE	22/07/24	675.95KB	Share
1AI	Quarterly Activities Report /Appendix 4C Cash Flow Statement	PRICE SENSITIVE	29/04/24	493.61KB	Share
1AI	Positive results from AI-116 in vitro studies	PRICE SENSITIVE	08/04/24	249.04KB	Share
1AI	Artificial Intelligence Platform Update	PRICE SENSITIVE	08/03/24	433.75KB	Share
1AI	Half Yearly Report Announcement and Appendix 4D	PRICE SENSITIVE	29/02/24	1022.96KB	Share
1AI	Response to ASX Price Query	PRICE SENSITIVE	20/02/24	739.7KB	Share
1AI	NTCELL Project Update	PRICE SENSITIVE	14/02/24	141.11KB	Share
1AI	Quarterly Activities Report/Appendix 4C Cash Flow Statement	PRICE SENSITIVE	30/01/24	477.38KB	Share
1AI	Agreement with HL Pharma Addendum	PRICE SENSITIVE	05/01/24	140.05KB	Share
1AI	Algorae to list existing Option series on ASX	PRICE SENSITIVE	05/12/23	137.04KB	Share
1AI	1AI commences AI-168 pre-clinical studies	PRICE SENSITIVE	23/11/23	153.29KB	Share
1AI	Addendum to September Quarterly Report	PRICE SENSITIVE	21/11/23	148.03KB	Share
1AI	CSIRO Grant for Artificial Intelligence Platform	PRICE SENSITIVE	31/10/23	185.96KB	Share
1AI	Quarterly Activities/Appendix 5B Cash Flow Report	PRICE SENSITIVE	27/10/23	276.17KB	Share
1AI	LCT commences AI-116 pre clinical studies	PRICE SENSITIVE	01/09/23	109.4KB	Share
1AI	Annual Report and Appendix 4E	PRICE SENSITIVE	30/08/23	1006.47KB	Share
1AI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/23	391.3KB	Share
1AI	Patent application over AI-116 for Dementia filed	PRICE SENSITIVE	26/07/23	101.34KB	Share
1AI	NTCELL Project Update	PRICE SENSITIVE	19/06/23	95.92KB	Share
1AI	LCT Announces Shortfall Completion Notice	PRICE SENSITIVE	03/05/23	94.41KB	Share
1AI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	177.37KB	Share
1AI	Rights Issue Prospectus	PRICE SENSITIVE	20/03/23	501.22KB	Share
1AI	APeT Cleansing Announcement	PRICE SENSITIVE	10/03/23	108.8KB	Share
1AI	Pause in Trading	PRICE SENSITIVE	10/03/23	116.69KB	Share
1AI	LCT Undertakes $2.5 Million Capital Raise Initiative	PRICE SENSITIVE	01/03/23	156.21KB	Share
1AI	Half Year Accounts and Appendix 4D	PRICE SENSITIVE	28/02/23	653.53KB	Share
1AI	Trading Halt	PRICE SENSITIVE	27/02/23	493.1KB	Share
1AI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/01/23	331.85KB	Share
1AI	Quarterly Activity Report and Appendix 4C	PRICE SENSITIVE	28/10/22	410.34KB	Share
1AI	New milestone for LCT's AI development	PRICE SENSITIVE	16/09/22	259.38KB	Share
1AI	Preliminary Final Report and 2022 Financial Statements	PRICE SENSITIVE	31/08/22	1.36MB	Share
1AI	Quarterly Activity Report and Appendix 4C	PRICE SENSITIVE	29/07/22	446.28KB	Share
1AI	LCT Completes Strategic A$1.285M Placement	PRICE SENSITIVE	31/05/22	166.01KB	Share
1AI	Trading Halt	PRICE SENSITIVE	27/05/22	208.41KB	Share
1AI	Quarterly Activity Report and Appendix 4C	PRICE SENSITIVE	29/04/22	478.69KB	Share
1AI	Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/22	550.97KB	Share
1AI	Quarterly Activity Report and Appendix 4C	PRICE SENSITIVE	31/01/22	533.33KB	Share
1AI	LCT Signs Service Agreement with NZeno	PRICE SENSITIVE	24/01/22	175.44KB	Share
1AI	Results of Rights Issue	PRICE SENSITIVE	29/12/21	114.29KB	Share
1AI	Extension of Rights Issue	PRICE SENSITIVE	09/12/21	140.21KB	Share
1AI	Prospectus- Rights Issue	PRICE SENSITIVE	15/11/21	922.76KB	Share
1AI	LCT- Rights Issue	PRICE SENSITIVE	15/11/21	443.48KB	Share
1AI	LCT Receives New Zealand R&D Tax Credit	PRICE SENSITIVE	09/11/21	449.56KB	Share
1AI	LCT Advises Price Change for Rights Issue	PRICE SENSITIVE	08/11/21	439.44KB	Share
1AI	Quarterly Activity Report and Appendix 4C	PRICE SENSITIVE	29/10/21	1.01MB	Share
1AI	LCT Signs MOU with NZeno, Secures Pig Cells for NTCELL Trial	PRICE SENSITIVE	26/10/21	538.33KB	Share
1AI	Secures Funds for 3rd Trial of NTCELL in Parkinson Disease	PRICE SENSITIVE	19/10/21	542.63KB	Share
1AI	Trading Halt	PRICE SENSITIVE	15/10/21	534.46KB	Share
1AI	Pause in Trading	PRICE SENSITIVE	15/10/21	116.88KB	Share
1AI	Preliminary Final Report and 2021 Financial Statements	PRICE SENSITIVE	31/08/21	1.41MB	Share
1AI	Quarterly Activity Report and Appendix 4C	PRICE SENSITIVE	30/07/21	1.03MB	Share
1AI	LCT Interim CEO Appointed	PRICE SENSITIVE	16/07/21	430.77KB	Share
1AI	Response to ASX Price Query	PRICE SENSITIVE	02/07/21	821.92KB	Share
1AI	Quarterly Activity Report and Appendix 4C	PRICE SENSITIVE	27/04/21	766.89KB	Share
1AI	LCT exits peptide projects	PRICE SENSITIVE	29/03/21	442.51KB	Share
1AI	Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/21	1.46MB	Share
1AI	Response to ASX Price Query	PRICE SENSITIVE	12/02/21	530.48KB	Share
1AI	Quarterly Activity Report and Appendix 4C	PRICE SENSITIVE	28/01/21	729.03KB	Share
1AI	LCT CEO Dr Ken Taylor signals intention to retire	PRICE SENSITIVE	25/01/21	432.48KB	Share
1AI	Quarterly Activity Report and Appendix 4C	PRICE SENSITIVE	28/10/20	763.59KB	Share
1AI	Preliminary Final Report and 2020 Financial Statements	PRICE SENSITIVE	31/08/20	1.43MB	Share
1AI	Amended Appendix 4C	PRICE SENSITIVE	30/07/20	1.08MB	Share
1AI	Quarterly Activity Report and Appendix 4C	PRICE SENSITIVE	30/07/20	821.96KB	Share
1AI	Response to ASX Aware Query	PRICE SENSITIVE	13/07/20	715.43KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/20	327.47KB	Share
1AI	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/20	1.28MB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/20	321.65KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	24/10/19	1.07MB	Share
1AI	LCT extends cash runway with receipt from Vertex acquisition	PRICE SENSITIVE	16/10/19	75.9KB	Share
1AI	LCT to benefit from Semma Therapeutics acquisition by Vertex	PRICE SENSITIVE	19/09/19	83.49KB	Share
1AI	Response to ASX Aware Query	PRICE SENSITIVE	17/09/19	471.52KB	Share
1AI	Preliminary Final Report and 2019 Financial Statements	PRICE SENSITIVE	29/08/19	698.61KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	26/07/19	310.08KB	Share
1AI	NTCELL Parkinsons trial patient data 2 years after implant	PRICE SENSITIVE	13/05/19	457.82KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	15/04/19	691.72KB	Share
1AI	Half Yearly Report and Accounts	PRICE SENSITIVE	19/02/19	850.35KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/19	698.49KB	Share
1AI	NTCELL Parkinsons trial patient data at 18 months	PRICE SENSITIVE	02/11/18	517.25KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	26/10/18	378.19KB	Share
1AI	Response to ASX Price Query	PRICE SENSITIVE	19/10/18	425.5KB	Share
1AI	Preliminary Final Report and 2018 Financial Statements	PRICE SENSITIVE	30/08/18	693.96KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	26/07/18	287.56KB	Share
1AI	NTCELL and Parkinsons trial update	PRICE SENSITIVE	15/05/18	213.1KB	Share
1AI	Appendix 4C - quarterly	PRICE SENSITIVE	26/04/18	870.32KB	Share
1AI	LCT Strategy Update	PRICE SENSITIVE	11/04/18	308.42KB	Share
1AI	LCT to sell JV Shares and receive DIABECELL licence	PRICE SENSITIVE	25/01/18	90.47KB	Share
1AI	Appendix 4C - Quarterly	PRICE SENSITIVE	24/01/18	339.43KB	Share

1AI Quarterly Activities Report /Appendix 4C Cash Flow Statement
29/07/25	PRICE SENSITIVE	1.01MB	Share
1AI Algorae Receives A$318,771 R&D Cash Rebate from ATO
06/06/25	PRICE SENSITIVE	186.28KB	Share
1AI Peter Mac Partners with Algorae on AI Drug Targets
08/05/25	PRICE SENSITIVE	256.29KB	Share
1AI Quarterly Activities Report /Appendix 4C Cash Flow Statement
29/04/25	PRICE SENSITIVE	977.98KB	Share
1AI Algorae Receives A$451,359 R&D Cash Rebate from ATO
31/03/25	PRICE SENSITIVE	186.37KB	Share
1AI Half Yearly Report Announcement and Appendix 4D
26/02/25	PRICE SENSITIVE	1.16MB	Share
1AI Quarterly Activities Report /Appendix 4C Cash Flow Statement
29/01/25	PRICE SENSITIVE	1.08MB	Share
1AI Significant Cardioprotection Qualities in AI-168 Studies
29/11/24	PRICE SENSITIVE	344.06KB	Share
1AI 24 New AI-Generated Drug Targets
21/11/24	PRICE SENSITIVE	261.28KB	Share
1AI Quarterly Activities Report /Appendix 4C Cash Flow Statement
23/10/24	PRICE SENSITIVE	527.26KB	Share
1AI AlgoraeOS Artificial Intelligence Platform Launched
24/09/24	PRICE SENSITIVE	17.67MB	Share
1AI Annual Report and Appendix 4E
30/08/24	PRICE SENSITIVE	1.2MB	Share
1AI Positive results from AI-116 in vitro studies
31/07/24	PRICE SENSITIVE	336.91KB	Share
1AI Quarterly Activities Report /Appendix 4C Cash Flow Statement
22/07/24	PRICE SENSITIVE	675.95KB	Share
1AI Quarterly Activities Report /Appendix 4C Cash Flow Statement
29/04/24	PRICE SENSITIVE	493.61KB	Share
1AI Positive results from AI-116 in vitro studies
08/04/24	PRICE SENSITIVE	249.04KB	Share
1AI Artificial Intelligence Platform Update
08/03/24	PRICE SENSITIVE	433.75KB	Share
1AI Half Yearly Report Announcement and Appendix 4D
29/02/24	PRICE SENSITIVE	1022.96KB	Share
1AI Response to ASX Price Query
20/02/24	PRICE SENSITIVE	739.7KB	Share
1AI NTCELL Project Update
14/02/24	PRICE SENSITIVE	141.11KB	Share
1AI Quarterly Activities Report/Appendix 4C Cash Flow Statement
30/01/24	PRICE SENSITIVE	477.38KB	Share
1AI Agreement with HL Pharma Addendum
05/01/24	PRICE SENSITIVE	140.05KB	Share
1AI Algorae to list existing Option series on ASX
05/12/23	PRICE SENSITIVE	137.04KB	Share
1AI 1AI commences AI-168 pre-clinical studies
23/11/23	PRICE SENSITIVE	153.29KB	Share
1AI Addendum to September Quarterly Report
21/11/23	PRICE SENSITIVE	148.03KB	Share
1AI CSIRO Grant for Artificial Intelligence Platform
31/10/23	PRICE SENSITIVE	185.96KB	Share
1AI Quarterly Activities/Appendix 5B Cash Flow Report
27/10/23	PRICE SENSITIVE	276.17KB	Share
1AI LCT commences AI-116 pre clinical studies
01/09/23	PRICE SENSITIVE	109.4KB	Share
1AI Annual Report and Appendix 4E
30/08/23	PRICE SENSITIVE	1006.47KB	Share
1AI Quarterly Activities/Appendix 4C Cash Flow Report
28/07/23	PRICE SENSITIVE	391.3KB	Share
1AI Patent application over AI-116 for Dementia filed
26/07/23	PRICE SENSITIVE	101.34KB	Share
1AI NTCELL Project Update
19/06/23	PRICE SENSITIVE	95.92KB	Share
1AI LCT Announces Shortfall Completion Notice
03/05/23	PRICE SENSITIVE	94.41KB	Share
1AI Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	177.37KB	Share
1AI Rights Issue Prospectus
20/03/23	PRICE SENSITIVE	501.22KB	Share
1AI APeT Cleansing Announcement
10/03/23	PRICE SENSITIVE	108.8KB	Share
1AI Pause in Trading
10/03/23	PRICE SENSITIVE	116.69KB	Share
1AI LCT Undertakes $2.5 Million Capital Raise Initiative
01/03/23	PRICE SENSITIVE	156.21KB	Share
1AI Half Year Accounts and Appendix 4D
28/02/23	PRICE SENSITIVE	653.53KB	Share
1AI Trading Halt
27/02/23	PRICE SENSITIVE	493.1KB	Share
1AI Quarterly Activities/Appendix 4C Cash Flow Report
27/01/23	PRICE SENSITIVE	331.85KB	Share
1AI Quarterly Activity Report and Appendix 4C
28/10/22	PRICE SENSITIVE	410.34KB	Share
1AI New milestone for LCT's AI development
16/09/22	PRICE SENSITIVE	259.38KB	Share
1AI Preliminary Final Report and 2022 Financial Statements
31/08/22	PRICE SENSITIVE	1.36MB	Share
1AI Quarterly Activity Report and Appendix 4C
29/07/22	PRICE SENSITIVE	446.28KB	Share
1AI LCT Completes Strategic A$1.285M Placement
31/05/22	PRICE SENSITIVE	166.01KB	Share
1AI Trading Halt
27/05/22	PRICE SENSITIVE	208.41KB	Share
1AI Quarterly Activity Report and Appendix 4C
29/04/22	PRICE SENSITIVE	478.69KB	Share
1AI Half Yearly Report and Accounts
25/02/22	PRICE SENSITIVE	550.97KB	Share
1AI Quarterly Activity Report and Appendix 4C
31/01/22	PRICE SENSITIVE	533.33KB	Share
1AI LCT Signs Service Agreement with NZeno
24/01/22	PRICE SENSITIVE	175.44KB	Share
1AI Results of Rights Issue
29/12/21	PRICE SENSITIVE	114.29KB	Share
1AI Extension of Rights Issue
09/12/21	PRICE SENSITIVE	140.21KB	Share
1AI Prospectus- Rights Issue
15/11/21	PRICE SENSITIVE	922.76KB	Share
1AI LCT- Rights Issue
15/11/21	PRICE SENSITIVE	443.48KB	Share
1AI LCT Receives New Zealand R&D Tax Credit
09/11/21	PRICE SENSITIVE	449.56KB	Share
1AI LCT Advises Price Change for Rights Issue
08/11/21	PRICE SENSITIVE	439.44KB	Share
1AI Quarterly Activity Report and Appendix 4C
29/10/21	PRICE SENSITIVE	1.01MB	Share
1AI LCT Signs MOU with NZeno, Secures Pig Cells for NTCELL Trial
26/10/21	PRICE SENSITIVE	538.33KB	Share
1AI Secures Funds for 3rd Trial of NTCELL in Parkinson Disease
19/10/21	PRICE SENSITIVE	542.63KB	Share
1AI Trading Halt
15/10/21	PRICE SENSITIVE	534.46KB	Share
1AI Pause in Trading
15/10/21	PRICE SENSITIVE	116.88KB	Share
1AI Preliminary Final Report and 2021 Financial Statements
31/08/21	PRICE SENSITIVE	1.41MB	Share
1AI Quarterly Activity Report and Appendix 4C
30/07/21	PRICE SENSITIVE	1.03MB	Share
1AI LCT Interim CEO Appointed
16/07/21	PRICE SENSITIVE	430.77KB	Share
1AI Response to ASX Price Query
02/07/21	PRICE SENSITIVE	821.92KB	Share
1AI Quarterly Activity Report and Appendix 4C
27/04/21	PRICE SENSITIVE	766.89KB	Share
1AI LCT exits peptide projects
29/03/21	PRICE SENSITIVE	442.51KB	Share
1AI Half Yearly Report and Accounts
25/02/21	PRICE SENSITIVE	1.46MB	Share
1AI Response to ASX Price Query
12/02/21	PRICE SENSITIVE	530.48KB	Share
1AI Quarterly Activity Report and Appendix 4C
28/01/21	PRICE SENSITIVE	729.03KB	Share
1AI LCT CEO Dr Ken Taylor signals intention to retire
25/01/21	PRICE SENSITIVE	432.48KB	Share
1AI Quarterly Activity Report and Appendix 4C
28/10/20	PRICE SENSITIVE	763.59KB	Share
1AI Preliminary Final Report and 2020 Financial Statements
31/08/20	PRICE SENSITIVE	1.43MB	Share
1AI Amended Appendix 4C
30/07/20	PRICE SENSITIVE	1.08MB	Share
1AI Quarterly Activity Report and Appendix 4C
30/07/20	PRICE SENSITIVE	821.96KB	Share
1AI Response to ASX Aware Query
13/07/20	PRICE SENSITIVE	715.43KB	Share
1AI Appendix 4C - quarterly
29/04/20	PRICE SENSITIVE	327.47KB	Share
1AI Half Yearly Report and Accounts
27/02/20	PRICE SENSITIVE	1.28MB	Share
1AI Appendix 4C - quarterly
30/01/20	PRICE SENSITIVE	321.65KB	Share
1AI Appendix 4C - quarterly
24/10/19	PRICE SENSITIVE	1.07MB	Share
1AI LCT extends cash runway with receipt from Vertex acquisition
16/10/19	PRICE SENSITIVE	75.9KB	Share
1AI LCT to benefit from Semma Therapeutics acquisition by Vertex
19/09/19	PRICE SENSITIVE	83.49KB	Share
1AI Response to ASX Aware Query
17/09/19	PRICE SENSITIVE	471.52KB	Share
1AI Preliminary Final Report and 2019 Financial Statements
29/08/19	PRICE SENSITIVE	698.61KB	Share
1AI Appendix 4C - quarterly
26/07/19	PRICE SENSITIVE	310.08KB	Share
1AI NTCELL Parkinsons trial patient data 2 years after implant
13/05/19	PRICE SENSITIVE	457.82KB	Share
1AI Appendix 4C - quarterly
15/04/19	PRICE SENSITIVE	691.72KB	Share
1AI Half Yearly Report and Accounts
19/02/19	PRICE SENSITIVE	850.35KB	Share
1AI Appendix 4C - quarterly
30/01/19	PRICE SENSITIVE	698.49KB	Share
1AI NTCELL Parkinsons trial patient data at 18 months
02/11/18	PRICE SENSITIVE	517.25KB	Share
1AI Appendix 4C - quarterly
26/10/18	PRICE SENSITIVE	378.19KB	Share
1AI Response to ASX Price Query
19/10/18	PRICE SENSITIVE	425.5KB	Share
1AI Preliminary Final Report and 2018 Financial Statements
30/08/18	PRICE SENSITIVE	693.96KB	Share
1AI Appendix 4C - quarterly
26/07/18	PRICE SENSITIVE	287.56KB	Share
1AI NTCELL and Parkinsons trial update
15/05/18	PRICE SENSITIVE	213.1KB	Share
1AI Appendix 4C - quarterly
26/04/18	PRICE SENSITIVE	870.32KB	Share
1AI LCT Strategy Update
11/04/18	PRICE SENSITIVE	308.42KB	Share
1AI LCT to sell JV Shares and receive DIABECELL licence
25/01/18	PRICE SENSITIVE	90.47KB	Share
1AI Appendix 4C - Quarterly
24/01/18	PRICE SENSITIVE	339.43KB	Share

REFRESH

1 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.6¢		Change 0.000(0.00%)		Mkt cap ! $10.96M

Open	High	Low	Value	Volume
0.6¢	0.7¢	0.6¢	$52.58K	8.060M

Buyers (Bids)

No.	Vol.	Price($)
11	4296515	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	837702	2

View Market Depth

No.	Vol.	Price($)
11	4296515	0.006
12	10056669	0.005
14	13997208	0.004
6	7530302	0.003
4	3900009	0.002

Price($)	Vol.	No.
0.007	837702	2
0.008	1207573	5
0.009	1324990	2
0.010	4632439	5
0.011	2498004	3

Last trade - 13.59pm 11/08/2025 (20 minute delay)


Last 0.6¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
0.6¢	0.7¢	0.6¢	2615125
Last updated 13.33pm 11/08/2025 ?

1AI (ASX) Chart

ALGORAE PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories